The characteristics of pharmacokinetics and the biological effects of gonadotropin-releasing hormone agonists
- Authors: Rukhliada N.N.1, Birukova E.I.2
-
Affiliations:
- Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia
- I.I. Dzhanelidze Saint Petersburg Research Institute of Emergence Care
- Issue: No 2 (2023)
- Pages: 154-158
- Section: Guidelines for the Practitioner
- URL: https://journals.eco-vector.com/0300-9092/article/view/340798
- DOI: https://doi.org/10.18565/aig.2023.42
- ID: 340798
Cite item
Open Access
Access granted
Abstract
This paper presents a literature review of the physiological and pharmacokinetic features of used gonadotropin-releasing hormone (GnRH) agonists. It considers in detail the mechanism of action of drugs of this group at the level of receptors, as well as their mediated physiological effects. GnRH agonists initially stimulate and then inhibit sex hormone secretion by desensitizing pituitary GnRH receptors. There are examples of the clinical use of GnRH agonists. The latter are used to treat hormone-dependent diseases, such as endometriosis, uterine leiomyoma, pubertas precox, breast cancer, as well as in assisted reproductive technology protocols. Decreased bone mineralization due to hypoestrogenism is known to be one of the extremely negative effects of long-term use of GnRH agonists. The article discusses the ways of reducing the frequency and severity of GnRH side effects, including add-back therapy or changing the regimen of prescribing GnRH agonists.
Conclusion: The introduction of GnRH agonists was another breakthrough in gynecological practice and made it possible to successfully overcome previously unsolvable problems, such as infertility, severe endometriosis. Further joint developments by physiologists, biochemists, and clinicians suggest the increase in the efficacy of drugs and the expansion of their therapeutic abilities while reducing the risks of their use.
Full Text
About the authors
Nikolai N. Rukhliada
Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia
Author for correspondence.
Email: nickolasr@mail.ru
ORCID iD: 0000-0002-3548-0468
Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology
Russian Federation, Saint PetersburgElena I. Birukova
I.I. Dzhanelidze Saint Petersburg Research Institute of Emergence Care
Email: 79112252131@yandex.ru
Ph.D., Head of the Department of Gynecology No. 2
Russian Federation, Saint PetersburgReferences
- Esencan E., Taylor H.S. Gonadotropin-releasing hormone antagonists revolutionizing gynecology. Obstet. Gynecol. 2022; 140(6): 917-9. https://dx.doi.org/10.1097/AOG.0000000000005012.
- Knobil E. The neuroendocrine control of menstrual cycle. Recent. Prog. Horm. Res. 1980; 36: 53-88. https://dx.doi.org/10.1016/b978-0-12-571136-4.50008-5.
- Tzoupis H., Nteli A., Androutsou M.E., Tselios T. Gonadotropin-releasing hormone and GnRH receptor: structure, function and drug development. Curr. Med. Chem. 2020; 27(36): 6136-58. https://dx.doi.org/10.2174/ 0929867326666190712165444.
- Burlev V.A., Kuz'michev L.N., Onishchenko A.C., Il'iasova N.A., Shchetinina N.C. Endometrial functional activity and the results of IVF: molecular mechanisms. Russian Journal of Human Reproduction. 2010; 16(2): 41-52. (in Russian).
- Newton C.L., Riekert C., Millar R.P. Gonadotropin-releasing hormone analog therapeutics. Minerva Ginecol. 2018; 70(5): 497-515. https://dx.doi.org/10.23736/S0026-4784.18.04316-2.
- Pratap A., Garner K.L., Voliotis M., Tsaneva-Atanasova K., McArdle C.A. Mathematical modeling of gonadotropin-releasing hormone signaling. Mol. Cell. Endocrinol. 2017; 449: 42-55. https://dx.doi.org/10.1016/j.mce.2016.08.022.
- Tavaniotou A., Smitz J., Bourgain С., Devroey P. Ovulation induction disrupts phase function. Ann. N. Y. Acad. Sci. 2001; 943: 55-63. https://dx.doi.org/10.1111/j.1749-6632.2001.tb03790.x.
- Voliotis M., Garner K.L., Alobaid H., Tsaneva-Atanasova K., McArdle C.A. Gonadotropin-releasing hormone signaling: An information theoretic approach. Mol. Cell. Endocrinol. 2018; 463: 106-15. https://dx.doi.org/10.1016/ j.mce.2017.07.028.
- Al-Sheyyab R.Y., Al-Taani B.M., Obeidat R.M., Alsmadi M.M., Masaedeh R.K., Sabat R.N. Delivery of peptidic gonadotropin releasing hormone antagonists. Curr. Drug Deliv. 2018; 15(5): 602-9. https://dx.doi.org/10.2174/ 1567201815666180214142300.
- De Sanctis V., Soliman A.T., Di Maio S., Soliman N., Elsedfy H. Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature. Acta Biomed. 2019; 90(3): 345-59. https://dx.doi.org/10.23750/abm.v90i3.8736.
- Lessey B.A. The role of the endometrium during embryo implantation. Hum. Reprod. 2000; 15(Suppl. 6): 39-50.
- Pirard C., Donnez J., Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum. Reprod. 2005; 20(7): 1798-804. https://dx.doi.org/10.1093/humrep/deh830.
- Gallyamova E.M., Perminova S.G., Mityurina E.V., Strelchenko D.A. Impact of luteal-phase support with a GnRH agonist on the outcomes of IVF programs. Obstetrics and Gynecology. 2015; (7): 48-55. (in Russian).
- Perminova S.G., Mityurina E.V., Savelyeva E.M. Opportunities for using gonadotropin-releasing hormone agonist for luteal phase support in the in vitro fertilization program. Obstetrics and Gynecology. 2018; (10): 72-9. (in Russian). https://dx.doi.org/10.18565/aig.2018.10.72-79.
- Della Corte L., Barra F., Mercorio A., Evangelisti G., Rapisarda A.M.C., Ferrero S., Bifulco G., Giampaolino P. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin. Drug Metab. Toxicol. 2020; 16(9): 759-68. https://dx.doi.org/10.1080/17425255.2020.1789591.
- Kosheleva N.M., Perminova S.G., Vlasova G.A., Kirillova A.O. Application of assisted reproductive technology programs in a female patient with systemic lupus erythematosus and antiphospholipid syndrome. Obstetrics and Gynecology. 2020; (4): 224-9. (in Russian). https://dx.doi.org/10.18565/ aig.2020.4.224-229.
- Bourgain C., Devroey P. The endometrium in stimulated cycles for IVF. Hum. Reprod. Update. 2003; 9(6): 515-22. https://dx.doi.org/10.1093/humupd/dmg045.
Supplementary files
